Cure8 research brief
People with IBD and coexisting primary sclerosing cholangitis (PSC) may get faecal calprotectin tests to monitor colon inflammation. If PSC raises FC independently of colitis, FC could mislead decisions about IBD activity and treatment.
Clinicians monitoring IBD activity with faecal calprotectin; gastroenterologists treating PSC-IBD; researchers of IBD biomarkers; patients with IBD and PSC.
The pooled analysis did not find a statistically significant difference in absolute FC values between PSC-IBD and IBD alone, but the evidence base is small (few cohorts) and certainty rated very low.
Qualitative data in the review suggest FC can be discordant with endoscopic colitis activity in PSC-IBD — FC was sometimes elevated even when endoscopy showed quiescent colitis and correlated with biliary calprotectin. The authors conclude FC may partly reflect biliary inflammation in PSC-IBD and recommend interpreting FC with caution in this subgroup.
This classification and note are grounded in the article abstract and structured summary. The review pooled a small number of cohorts and rated evidence certainty as very low; findings are hypothesis-generating and require adequately powered prospective validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
